BAM-15 Tablets

BAM-15 Tablets Oral Delivery Profile

BAM-15 Tablets represents an advanced oral delivery system, engineered to survive gastrointestinal degradation and provide systemic biological activity without the need for traditional parenteral injection.

Pharmacological Architecture

Parameter	Value
Molecular Formula	C16H12F3N5O
Molecular Mass	347.3 g/mol
Assay Purity	>99.0%
Appearance	Off-white compressed tablets

Figure 1: BAM-15 Tablets GI Tract Dissolution & Absorption

Oral Mechanism of Action

Detailed cascade of actions from ingestion to systemic effect:

1. Acts as a selective mitochondrial protonophore (uncoupler of oxidative phosphorylation).
2. Allows protons to leak back across the inner mitochondrial membrane without ATP generation.
3. Forces mitochondria to burn calories as pure heat (non-shivering thermogenesis) to compensate.
4. Drastically increases resting energy expenditure even at absolute physical rest.
5. Does NOT deplete membrane potential to lethal levels like older uncouplers (DNP).

Figure 2: Rate of Oral Systemic Bioavailability

Primary Research Results

• Outcome 1: Considered the ultra-safe successor to 2,4-dinitrophenol (DNP) for metabolic research.
• Outcome 2: Produces dramatic body fat reduction without lowering muscle tissue or total body protein.
• Outcome 3: One of the only orally available mitochondrial uncouplers with a wide therapeutic safety margin.

Mitochondrial Uncoupling Pharmacology

BAM-15 is a mitochondrial protonophore uncoupler that dissipates the proton gradient across the inner mitochondrial membrane, converting the energy stored in the electrochemical gradient into heat rather than ATP. Unlike classical uncouplers such as 2,4-dinitrophenol (DNP), BAM-15 exhibits a uniquely favorable safety profile: it uncouples oxidative phosphorylation at doses that increase energy expenditure without raising core body temperature to dangerous levels or causing the runaway hyperthermia that made DNP lethal.

1. BAM-15 inserts into the inner mitochondrial membrane and facilitates proton translocation from the intermembrane space to the matrix, bypassing ATP synthase (Complex V).
2. The dissipated proton-motive force forces the electron transport chain to increase substrate oxidation (fat and glucose) to maintain the membrane potential.
3. Increased substrate oxidation without increased ATP production results in energy dissipation as heat—the thermogenic basis of mitochondrial uncoupling.
4. BAM-15 preferentially depolarizes mitochondria to a moderate extent, reducing reactive oxygen species (ROS) production at Complex I and III, providing antioxidant benefit.
5. Unlike DNP, BAM-15 does not uncouple plasma membrane potential and shows no toxicity at 10x the effective dose in cellular assays, establishing a wide therapeutic window.

Research Data & Metabolic Effects

• Obesity Prevention: BAM-15 (oral, 50 mg/kg/day) prevented weight gain in high-fat diet-fed mice without reducing food intake, confirming an energy expenditure mechanism.
• Existing Obesity: In already-obese mice, BAM-15 reduced body fat by 20–25% over 6 weeks while preserving lean mass, with no evidence of compensatory hyperphagia.
• Insulin Sensitivity: BAM-15-treated mice showed improved glucose tolerance, reduced fasting insulin, and decreased hepatic steatosis independent of weight loss kinetics.
• Safety Margin: No mortality, hyperthermia, or tachycardia observed in rodent studies at doses up to 200 mg/kg, in stark contrast to DNP’s narrow toxic window.
• Oral Format: BAM-15’s small molecular weight (MW 340 Da) and moderate lipophilicity provide excellent oral bioavailability, making tablets the preferred research delivery format.